Therapeutic Discovery Articles & Analysis
33 news found
This enhancement aims to offer more precise and comprehensive glycoprotein analysis, catering to the growing demands in the fields of biomedical research, disease biomarker discovery, and therapeutic development. Protein glycosylation, a major post-translational modification, significantly impacts protein folding, stability, and activity. ...
Stem cells have revolutionized cell-based therapeutics, drug discovery and many other scientific fields. However, despite significant advancements in iPSC culture, several challenges remain regarding the reliability, reproducibility and consistency of cell cultures, assays and data. ...
This opens new avenues for groundbreaking discoveries and therapeutic breakthroughs. High-Throughput and Swift Turnaround: CD Genomics' cutting-edge NGS platform enables the simultaneous analysis of multiple samples, significantly reducing turnaround times without compromising data quality. ...
This service has the potential to transform our understanding of complex protein-protein interactions, opening new avenues for advancements in drug discovery and therapeutic development. Protein-protein interactions serve as the building blocks of various cellular processes, orchestrating critical functions within living organisms. Gaining a deeper ...
Our unique combination of tissue engineering technology with assay automation and sample miniaturization offers a rapid and cost effective platform for unprecedented therapeutic discovery. IVS is addressing a significant, well-recognized but underserved problem with a technology that can effectively fill the gap in the existing large market. ...
Our unique combination of tissue engineering technology with assay automation and sample miniaturization offers a rapid and cost effective platform for unprecedented therapeutic discovery. IVS is addressing a significant, well-recognized but underserved problem with a technology that can effectively fill the gap in the existing large market. ...
With this shift in our leadership team, we hope to continue our journey of rapid growth and expansion delivering world class iPSC-based solutions to therapeutic developers. We are continuing to build our leadership teams by recruiting Gustavo Mahler as Chief Executive Officer. ...
Unlike other traditional and newer AI-driven methods of drug discovery that often focus upon dominant epitopes, the RubrYc Discovery Engine uses predictive algorithms to identify and model subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. ...
HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates against a second target for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP). This milestone marks the fifth payment that HemoShear has earned in ...
Jubilant Therapeutics Inc., a biopharmaceutical Company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced U.S. ...
Oxford, UK – July 20, 2021 – Orbit Discovery Ltd., (“Orbit”), a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, today announced that it has raised $7.6 million in funding. ...
Oxford, United Kingdom, 13th June, 2022: Orbit Discovery Ltd., (“Orbit”) a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, has been awarded a Smart grant by Innovate UK, the UK’s innovation agency. ...
The Stem Cell Spaceshot Grant is open to PhD-level scientists and PhD students conducting research in stem cell biology, biophysics, gene editing, cell therapy, and bioproduction engineering. With this grant, TreeFrog Therapeutics aims at supporting scientific discoveries with therapeutic impact in 4 areas: PROGRESSING STEM CELL ...
This powerful technology enables investigation of human B- and T-cell responses for a variety of applications, including antibody discovery and therapeutic immunogenicity,” said Melanie P. Matheu, PhD, Founder and CEO of Prellis Biologics. ...
The partnership underlines the commitment of the new management team to deliver ground-breaking technology and broader capabilities to the Partners engaged in applying the Company’s technology for the discovery of peptide therapeutic leads. Dr Neil Butt, Chief Executive Officer of Orbit Discovery, commented: “We aim to move Orbit to ...
Ghent, Belgium, December 15, 2021 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has extended its patent estate with four key US and EU patents granted as part of the company’s foundational “Steyaert patents”. ...
” https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz.12392 About C2N Diagnostics, LLC C2N Diagnostics’ vision is to bring Clarity Through Innovation™. It focuses its therapeutic discovery efforts around mechanism-based approaches to prevent or stop the progression of human neurological disorders. ...
HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP). ...
“Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients,” said Clive R. ...
About C2N Diagnostics, LLC C2N’s Diagnostics’ vision is to bring Clarity Through Innovation™. It focuses its therapeutic discovery efforts around mechanism-based approaches to prevent or stop the progression of human neurological disorders. ...